Funding
Seed+ · Biotech

Ingenix raises €13m Seed+ for drug-development AI

Sofinnova Partners, Inovo VC and OTB Ventures participated in the financing.

Updated Oct 16, 2026By RoundOS Funding desk

Ingenix raised €13 million in Seed+ financing on June 3. Participants included Sofinnova Partners, Inovo VC and OTB Ventures. The company combines biological data modalities in AI systems for pharmaceutical and biotechnology drug development.

Funding history

Seed+ · This round€13M

Sources

  1. Ingenixprojectstartups.com
  2. prnewswire.com

Similar rounds

All Biotech rounds →
Guoke Brain-Computer

Beijing startup developing non-invasive wearable brain-computer interfaces that combine brain-signal detection, decoding and neural modulation.

UndisclosedSeed · Oct 23, 2026
Star Therapeutics

Biotechnology company discovering and developing antibody therapies for diseases with significant unmet need.

$200MPrivate financing · Oct 23, 2026
Pathos AI

Clinical-stage drug developer using AI to select therapeutic assets and guide oncology trials.

$237MSeries E · Oct 23, 2026
Knowledge Work

Tokyo software company developing sales AI agents, an agent operating platform and consulting services for enterprise sales teams.

¥4.8BSeries C debt second close · Oct 23, 2026

Related